A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population

Mechanisms explaining the relationship in non‐alcoholic fatty liver disease (NAFLD), obesity, and insulin resistance are poorly understood. A genetic basis has been suggested. We studied the association between the genes patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) and apolipoprotein C3 (APOC3) and metabolic and histological parameters of NAFLD in obese patients.

[1]  N. Lundbom,et al.  Genetic variation in PNPLA3 but not APOC3 influences liver fat in non‐alcoholic fatty liver disease , 2012, Journal of gastroenterology and hepatology.

[2]  Hongyu Zhao,et al.  Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents , 2012, Hepatology.

[3]  M. Zappa,et al.  The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. , 2011, Journal of hepatology.

[4]  Jonathan C. Cohen,et al.  Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease* , 2011, The Journal of Biological Chemistry.

[5]  F. Leonetti,et al.  Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans , 2011, Lipids in Health and Disease.

[6]  S. Sookoian,et al.  Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease , 2011, Hepatology.

[7]  M. Taskinen,et al.  Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[8]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[9]  Udo Hoffmann,et al.  Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits , 2011, PLoS genetics.

[10]  Jonathan C. Cohen,et al.  Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance , 2011, Hepatology.

[11]  V. Wong,et al.  Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground , 2011, Journal of gastroenterology and hepatology.

[12]  Cameron D. Palmer,et al.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease , 2010, Hepatology.

[13]  T. Liang,et al.  The association of genetic variability in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease , 2010, Hepatology.

[14]  E. Bugianesi,et al.  Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease , 2010, Hepatology.

[15]  E. Brunt,et al.  Nonalcoholic fatty liver disease: pathology and pathogenesis. , 2010, Annual review of pathology.

[16]  E. Brunt.  Histopathology of non-alcoholic fatty liver disease. , 2009, Clinics in liver disease.

[17]  S. Sookoian,et al.  A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity , 2009, Journal of Lipid Research.

[18]  F. Kronenberg,et al.  A common variant in the adiponutrin gene influences liver enzyme values , 2009, Journal of Medical Genetics.

[19]  M. Ridderstråle,et al.  A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans , 2009, Diabetologia.

[20]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[21]  A. Prentice.  The emerging epidemic of obesity in developing countries. , 2006, International journal of epidemiology.

[22]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[23]  E. Brunt,et al.  Pathological features of NASH. , 2005, Frontiers in bioscience : a journal and virtual library.

[24]  J. George,et al.  Fatty liver disease: NASH and related disorders , 2004 .

[25]  D. Joy,et al.  Diagnosis of fatty liver disease: is biopsy necessary? , 2003, European journal of gastroenterology & hepatology.

[26]  J. Seidell,et al.  Techniques for the measurement of visceral fat: a practical guide. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[27]  P. Angeli,et al.  Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. , 1992, Gut.

[28]  J. Breslow,et al.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. , 1990, Science.

[29]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[30]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[31]  J. Maxwell,et al.  Ultrasound scanning in the detection of hepatic fibrosis and steatosis. , 1986, British medical journal.

[32]  C. L. Jackson,et al.  Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages. , 1985, Biochemistry.

[33]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[34]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[35]  L. N. Valenti,et al.  Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[36]  Wj Gauderman,et al.  QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies , 2006 .

[37]  David O. Cosgrove,et al.  Abdominal and general ultrasound , 1993 .

[38]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[39]  A. Rosenfield,et al.  Scintigraphy, ultrasound and CT scanning of the liver. , 1979 .